天竺综保区进出口值连续三年突破千亿

Core Insights - The Beijing Tianzhu Comprehensive Bonded Zone achieved a total import and export value of 109.23 billion yuan from January to November 2025, maintaining a stable scale above 100 billion yuan for three consecutive years [1] - The import value reached 105.06 billion yuan, while the export value was 4.17 billion yuan, with significant growth in cross-border pharmaceutical trade, particularly non-vaccine drug imports, which amounted to approximately 82.395 billion yuan, reflecting a year-on-year increase of 27.47% [1] Group 1: Pharmaceutical Trade Highlights - The import of rare disease drugs in the Tianzhu Comprehensive Bonded Zone was particularly noteworthy, with an import value of 3.16 billion yuan from January to October 2025, marking an 83% increase and accounting for 97% of the rare disease drug imports in Beijing during the same period [3] - The growth in rare disease drug imports is attributed to a policy initiative from the State Council at the end of 2023, which supported the establishment of a rare disease drug guarantee pilot zone in Tianzhu [3] - The Tianzhu zone has established a "white list" of first batch import enterprises, facilitating the import of specialized drugs and enhancing operational efficiency [3] Group 2: Operational Efficiency and Growth - The Tianzhu Comprehensive Bonded Zone has implemented various innovative measures to optimize the business environment, such as multiple declarations for a single customs clearance and intelligent management at checkpoints, which have significantly improved trade efficiency [4] - The import scale of medical products in the zone has grown from 24.9 billion yuan in 2019 to 47.5 billion yuan in 2025, demonstrating substantial business growth [4] - Cultural trade has emerged as a new growth point, with cultural product import and export value exceeding 200 million yuan in the first three quarters, reflecting a year-on-year increase of 140% [4] Group 3: Future Development Plans - The Tianzhu Comprehensive Bonded Zone plans to leverage the establishment of the rare disease drug guarantee pilot zone to further enhance policy advantages and promote high-level institutional openness [5] - The focus will be on optimizing the international service environment to support high-quality development of the air economy [5]